RC
FDMT icon

Rangeley Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Rangeley Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Sell
20,965
-10,500
-33% -$102K 0.25% 95
2026
Q1 		$293K Sell
31,465
-7,200
-19% -$62.7K 0.28% 74
2025
Q4 		$290K Sell
38,665
-4,000
-9% -$40.6K 0.24% 72
2025
Q3 		$371K Buy
42,665
+29,665
+228% +$177K 0.32% 64
2025
Q2 		$48.2K Buy
+13,000
New +$45.7K 0.06% 61

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Rangeley Capital's FDMT Position: Q2 2026 in Review

Rangeley Capital reduced its 4D Molecular Therapeutics (FDMT) stake by 33% in Q2 2026, selling an estimated $102K and leaving 20,965 shares worth $279K. The position accounts for 0.25% of the portfolio, ranked #95.

Rangeley Capital first reported a position in FDMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $371K in Q3 2025. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Rangeley Capital held 20,965 shares of 4D Molecular Therapeutics worth $279K as of Q2 2026.
  • Rangeley Capital sold 10,500 4D Molecular Therapeutics shares in Q2 2026, an estimated $102K.
  • 4D Molecular Therapeutics made up 0.25% of Rangeley Capital's portfolio in Q2 2026, its #95 holding.
  • Rangeley Capital first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Rangeley Capital's 4D Molecular Therapeutics position peaked at $371K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.